📅 PUBMED DAILY TRIAGE — 2026-06-26

Window: 2026-06-25T09:00:00Z → 2026-06-26T09:00:00Z (CRDT)
Topics scanned: 9 | Articles reviewed: ~75 candidates across all topics | Candidates evaluated: 26 scored
High priority: 4 | Standard: 16 | Low/archive: 6 | Unsolicited finds: 0
Run status: ⚠️ PARTIAL_SUCCESS (T1/T3/T4/T6 result sets exceeded fetch budget; T9 rare diseases = 0 results)

🔴🟠 HIGH PRIORITY (8+) — Best Finds by Topic

Novel therapeutics: immunotherapy, CAR-T, targeted therapy

pub-2026-06-26-001 · PMID 42350643 · Neoadjuvant SBRT + durvalumab + oleclumab in ER+HER2- breast cancer (Neo-CheckRay) · 9/10 🟠
→ Nat Med randomized phase 2 (n=147): in PD-L1-negative tumors, iSBRT + dual ICI (anti-PD-L1 + anti-CD73) raised pCR from 3.4% → 30%, converting immune-cold tumors to inflamed via TME reprogramming — first RCT evidence of this mechanism.

Early cancer detection (liquid biopsy, ctDNA, cfDNA)

pub-2026-06-26-002 · PMID 42348190 · DAPHNe trial: 5yr outcomes + ultrasensitive ctDNA in HER2+ BC · 8/10 🔴
→ JAMA Oncol: 5-yr EFS 99%, distant RFI 100% for abbreviated 12-wk THP; ctDNA cleared in 96.1% post-NAC — strong support for ctDNA-guided de-escalation in early HER2+ BC.

AI/ML in clinical diagnostics and imaging

pub-2026-06-26-003 · PMID 42350713 · Deep learning MRI radiomics reveals biological subtypes in rectal cancer · 8/10 🟢
→ NPJ Precis Oncol: multicenter (n=2060, 4 cohorts, external validation), DL subtypes mapped to immune phenotypes by scRNA-seq; RRS+clinical AUC 0.834 vs 0.780 in external validation — biologically grounded, near-term implementable.

Aging, longevity, and population health

pub-2026-06-26-004 · PMID 42348807 · Alpha-synuclein CSF SAA in autopsy-confirmed incidental Lewy body disease · 8/10 🔴
→ Neurology: CSF aSyn RT-QuIC achieves 75.8% sensitivity for prodromal ILBD at Stage I-II (olfactory bulb only), vs only 35% for skin/SMG — first evidence for CSF-based presymptomatic PD detection before motor onset.

🟢⚪ STANDARD (5–7) — Top by Topic

T1 · Hematologic Malignancies

• 42350367 · R/R classic Hodgkin lymphoma outcomes after frontline BV-AVD · 7/10 · Treatment Innovation — Blood Cancer J multi-institutional (n=116); PD-1 first salvage improves post-ASCT PFS (76% vs 59%, HR 0.31); primary refractory after BV-AVD flagged as unmet need.
• 42350047 · IL4Rα blockade in mycosis fungoides TME · 7/10 · Treatment Innovation — J Immunother Cancer; dupilumab repurposing for cutaneous TCL; CITEseq/ML shows STAT6 → malignant lymphocyte + immunosuppressive TME suppression.
• 42350371 · MCL-1 + ETC complex I synthetic lethality in AML (KMT2A-r) · 5/10 · Drug Development — Cell Death Dis; St. Jude preclinical PDX; HRI-DELE1-ATF4 stress response mechanism; cap applied (preclinical).

T2 · CBC-based Diagnostics + ML

• 42346448 · ECG + CBC + ML multimodal prediction in Kawasaki disease · 6/10 · Diagnostics — J Cardiovasc Dev Dis; prospective n=255; AUC 0.92 for CAL and IVIG resistance; open access PMC.

T3 · Early Cancer Detection

• 42350952 · CEMIP1 + TACSTD2 circulating mRNA biomarkers for CRC early detection · 7/10 · Early Detection — Mol Med; multi-phase discovery+validation; TACSTD2 for adenomas, CEMIP1 tracks tumor burden + declines post-resection; n=245 across CRA/CRC/controls.
• 42350190 · Multi-omics EV cargo in cancer (review) · 5/10 · Early Detection — Trends Cancer; field-synthesizing EV multi-omics review; standard workflow gaps identified.

T4 · AI/ML in Clinical Diagnostics

• 42349428 · OpenIO: AI-native immunotherapy framework · 7/10 · Treatment Innovation — Cancer Cell; generative AI + omics foundation models for rational immunotherapy design; international consortium (Fudan, MIT, Princeton, ByteDance).
• 42349759 · Prospective AI video databank for GI endoscopy · 5/10 · Diagnostics — Gastrointest Endosc; prospective infrastructure for AI validation in colonoscopy; addresses GI AI reproducibility gap.

T5 · Precision Oncology

• 42349246 · Very early-onset mCRC (30-39y) — distinct genomics and survival · 7/10 · Genomics/Precision Medicine — ESMO Open; multi-institutional n=264; shorter OS (30 vs 38m), KRAS enrichment (55% vs 42%), more peritoneal mets; defines ultra-young CRC subtype.
• 42348103 · Real-world NGS actionable alterations in NSCLC: meta-analysis · 6/10 · Genomics/Precision Medicine — Clin Transl Oncol; systematic review characterizing driver prevalence by region for precision oncology test utilization.
• 42350191 · Precision neuro-oncology for children (review) · 5/10 · Genomics/Precision Medicine — Trends Cancer; advocacy review for pediatric CNS tumor precision approaches; unmet need population.

T6 · Novel Therapeutics

(Best: 42350643 — see HIGH section above)

• 42350367 & 42350047 — see T1 above (cross-topic match)

T7 · Cardiovascular-Metabolic

• 42350670 · Liraglutide metabolic-state-dependent mechanisms (brain vs islet) · 7/10 · Drug Development — Diabetologia; human islets n=112 + tanycyte KO mice; healthy → brain-mediated, pre-DM → direct islet, advanced T2D → insulin-independent; patient stratification framework.
• 42350337 · Fitbit cardiometabolic risk reduction RCT · 6/10 · Prevention — JMIR mHealth; RCT wearable digital intervention; directly implementable cardiometabolic tool.
• 42350020 · MASLD body composition and all-cause mortality (NHANES) · 6/10 · Public Health — BMJ Open; population-based MASLD mortality by fat distribution phenotype; GLP-1 target population data.
• 42349741 · GLP-1 neural mechanisms: satiety to substance use (review) · 5/10 · Drug Development — Biol Psychiatry; GLP-1R agonists in addiction/reward circuits; expands GLP-1 therapeutic scope.

T8 · Aging, Longevity, Population Health

(Best: 42348807 — see HIGH section above)

• 42348207 · Diet quality and dementia risk with Alzheimer pathology · 7/10 · Prevention — JAMA Netw Open; prospective Swedish cohort; Mediterranean-DASH diet attenuates conversion in biomarker-confirmed preclinical AD; directly actionable.
• 42348295 · Primate-specific LINC01021 lncRNA in cellular and organismal aging · 6/10 · Genomics/Precision Medicine — Aging Cell; DAZAP1-RBMX mechanism; primate-specific aging pathway; open access.

T9 · Rare Diseases

No high-priority finds today. T9 returned 0 results in the 24-hour CRDT window.

💡 UNSOLICITED FINDS

None identified in this run. Sentinel scan articles overlapped substantially with watchlist topics.

📊 TODAY'S BREAKDOWN

By research category:

• Treatment Innovation: 5
• Early Detection: 4
• Diagnostics: 4
• Genomics/Precision Medicine: 4
• Drug Development: 3
• Prevention: 3
• Public Health: 2
• Other: 1

By evidence maturity:

• Potentially Practice-Changing: 2 (PMID 42350643, 42348190)
• Validated: 9
• Exploratory: 9

By watchlist topic (reviewed / kept / highest score):

By source type: peer_reviewed 26 | preprint 0

Topics with zero 8+ articles this run: T1 (best: 7), T2 (best: 6), T5 (best: 7), T6 (best: 9 via Neo-CheckRay), T7 (best: 7)
(Note: T6 produced the run's top-scoring article at 9/10)

🔧 RUN NOTES

• PARTIAL_SUCCESS: T1 (81 raw hits), T3 (36), T4 (37), T6 (120) result sets exceeded fetch budget for full 20-PMID abstract review; covered top 10-12 per topic.
• T9 rare diseases: 0 results — no window expansion triggered as other topics produced well above the 5-article threshold.
• T2 sparse: Only 1 result in window. No fallback query needed; article 42346448 retained as STANDARD.
• Topic mismatch exclusion: PMID 42350005 (BMJ Open, influenza vaccine immune response) was returned by T1 hematologic search but excluded after title review — not related to hematologic malignancy.
• Sentinel scan: 37 results, top 10 reviewed; all top-scoring sentinel candidates already captured in watchlist topics (42350643, 42348190, 42350713, 42348807).
• T7 esummary truncation: First T7 batch (42351151, 42350845) partially truncated; 42351151 and 42350845 metadata not fully retrieved; these articles not included in final scored output due to metadata gap.
• Previous run: 2026-06-25T09:00:00Z. 0 PMIDs deduplicated from prior emitted fingerprints.
• State checkpoint updated: state.json written with run timestamp and new emitted fingerprints.